Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Neuroblastoma Market In 2029?
There has been robust growth in the neuroblastoma market in recent years. The market is projected to expand from a $2.97 billion valuation in 2024 to $3.14 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 5.7%. The upward trend during the historical period is due to several factors, including a rise in neuroblastoma cases, heightened research and development activities for pediatric neuroblastoma therapies, an increasing rate of cancer among children, and growing governmental funding and support.
The market size for neuroblastoma is anticipated to witness substantial growth in the coming years, reaching$3.91 billion in 2029″ with a compound annual growth rate (CAGR) of 5.6%. The projected rise during this forecast period can be associated with numerous factors such as the rise in government funding, an upward trend in the disease incidence, intensifying efforts towards early diagnosis, an escalating frequency of genetic mutations, and progressing understanding and research. The forecast period is also expected to see certain key trends such as the creation of drugs targeting specific molecular pathways, breakthroughs in non-invasive imaging technologies, advancements in gene-editing methods, an increasing emphasis on personalized treatment, and the creation of radiolabeled compounds.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
Which Primay Drivers Are Accelerating Growth in the Neuroblastoma Market?
Anticipated growth in the neuroblastoma market is largely due to the increasing occurrence of cancer in children. Childhood cancer encompasses a range of cancers that usually strike children and adolescents, frequently targeting organs such as the brain, blood, and bones. Requiring unique treatment plans, its incidence is on the rise due to factors like enhanced diagnostic methods, increased awareness, environmental exposures, genetic predilections, and progress in medical study. Targeted therapies for childhood cancer are offered through neuroblastoma treatment, enabling early intervention that is efficacious and reduces chances of relapse, thereby improving results for young among patients. For instance, the American Cancer Society, a professional organization in the US, projected that around 9,620 children under the age of 15 are expected to be diagnosed with cancer in the year 2024, reflecting an increase from the 5,290 cases in 2023. Hence, the rise in childhood cancer incidence is fueling the growth of the neuroblastoma market.
Which Primary Segments of the Neuroblastoma Market Are Driving Growth and Industry Transformations?
The neuroblastomamarket covered in this report is segmented –
1) By Product Types: Tablets; Vaccines; Other Product Types
2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
3) By Distribution Channel: Online; Offline
4) By End-User: Hospitals; Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Neuroblastoma Market?# Market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Neuroblastoma Industry Dynamics?
Leading businesses in the neuroblastoma market are concentrating on formulating cutting-edge therapeutic treatments, such as humanized anti-GD2 monoclonal antibodies, to specifically target and safely combat cancer cells. The humanized anti-GD2 monoclonal antibody is structured to aim at the GD2 molecule on cancer cells and diminish immune rejection by incorporating human elements. For example, in August 2023, Renaissance Pharma Ltd., a clinical-stage pharmaceutical company from the UK, divulged the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is intended to address newly diagnosed high-risk neuroblastoma, which is a rare and aggressive pediatric cancer. As per the agreement’s terms, Renaissance has obtained exclusive authority to develop, produce, and market Hu14.18 in significant world markets like the United States, Canada, Europe, China, Japan, and Turkey.
View the full report here:
https://www.thebusinessresearchcompany.com/report/neuroblastoma–global-market-report
What Parameters Are Used to Define the Neuroblastoma Market?
Neuroblastoma is a type of cancer that primarily affects children and arises from immature nerve cells called neuroblasts. It commonly develops in the adrenal glands, located on top of the kidneys, and occurs in other areas of the abdomen, chest, neck, or pelvis. The cancer can cause symptoms such as abdominal pain, swelling, fatigue, and sometimes bone pain or lumps.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model